X
Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech roles
https://pharmaphorum.com/news/ex-roche-novartis-astrazeneca-leaders-appointed-to-biotech-roles/
Immunocore
Immunocore’s rare cancer treatment gains UK Promising Medicine designation
Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.
Immunocore hires Lilly’s Hotchkiss as chief commercial officer
UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.
Immunocore’s T-cell therapy could provide HIV cure
Treatment promises cure by reactivating immune cells to kill latent HIV-infected cells.
